Press Releases | Medtronic

Month Year

Email alerts

Apr 10, 2012

Medtronic Receives FDA Approval to Treat Mildly Symptomatic Heart Failure Patients Through Expanded Indication for CRT-D

Pivotal REVERSE & Landmark RAFT Clinical Trials Demonstrate Reduction in Mortality and Heart Failure Hospitalization Rates in New Patient Population

MINNEAPOLIS--(BUSINESS WIRE)--Apr. 10, 2012-- Medtronic, Inc. (NYSE: MDT) today announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for its cardiac...
Mar 30, 2012

Medtronic Reaches Settlement of Shareholder Class Action

MINNEAPOLIS--(BUSINESS WIRE)--Mar. 30, 2012-- Medtronic, Inc. (NYSE: MDT) today announced that the company has reached an agreement in principle to settle a previously disclosed federal securities...
Mar 26, 2012

Medtronic-Sponsored Study Finds Pacemakers Reduce Fainting in Patients

ACC.12 Late-breaker Shows Promise of Pacemakers through Diminishing Fainting Recurrences in Patients Diagnosed with Syncope

MINNEAPOLIS & CHICAGO--(BUSINESS WIRE)--Mar. 26, 2012-- Medtronic, Inc. (NYSE: MDT) today announced the results of a double-blind, randomized study, ISSUE-3, which found that patients who suffered...
Mar 25, 2012

Medtronic Symplicity™ Renal Denervation System Demonstrates Significant and Sustained Blood Pressure Reduction out to Three Years

Data from Two Clinical Trials Presented at the 61st Annual Scientific Session of the American College of Cardiology Show Consistent Effectiveness and Safety Up to Three Years

MINNEAPOLIS & CHICAGO--(BUSINESS WIRE)--Mar. 25, 2012-- Medtronic, Inc. (NYSE:MDT), announced that the Symplicity™ renal denervation system provides safe, significant and sustained blood...
Mar 24, 2012

Data Presented at ACC Reinforce Positive Clinical Outcomes for Patients Receiving Medtronic’s CoreValve® System

MINNEAPOLIS--(BUSINESS WIRE)--Mar. 24, 2012-- Medtronic, Inc. (NYSE: MDT) today announced results from its largest international, prospective, single-arm clinical trial evaluating the Medtronic...
Mar 24, 2012

Medtronic Resolute® Drug-Eluting Stent Delivers Durable Clinical Outcomes Through Two Years in Major Studies

Recently FDA-Approved, Novel Heart Device Shows Consistently Low Event Rates Across Broad Spectrum of Coronary Artery Disease Patients, Including Those with Diabetes

CHICAGO--(BUSINESS WIRE)--Mar. 24, 2012-- According to new clinical data presented today at ACC.12 –– the 61st Annual Scientific Session & Expo of the American College of Cardiology (ACC)...
Mar 15, 2012

Medtronic Receives Health Canada License for Deep Brain Stimulation Therapy in Refractory Epilepsy Patients

Another Medtronic First in Neuromodulation in Canada

BRAMPTON, Ontario & MINNEAPOLIS--(BUSINESS WIRE)--Mar. 15, 2012-- Medtronic, Inc. (NYSE: MDT) today announced that it has received from Health Canada a license for Medtronic Deep Brain Stimulation...
Mar 14, 2012

Medtronic Announces Public Offering of Senior Notes

MINNEAPOLIS--(BUSINESS WIRE)--Mar. 14, 2012-- Medtronic, Inc. (NYSE:MDT) today announced a registered offering of $675 million of its 3.125% Senior Notes due 2022 and $400 million of its 4.50%...
Mar 7, 2012

Medtronic CFO Gary Ellis to Speak at Barclays Capital Global Healthcare Conference

MINNEAPOLIS--(BUSINESS WIRE)--Mar. 7, 2012-- Medtronic, Inc. (NYSE: MDT), the world’s leading medical technology company, today announced it will participate in the Barclays Capital Global...
Mar 5, 2012

Medtronic Receives CE Mark for Pacemaker Lead That Will Expand Patient Access to MRI Technology

CapSure Sense MRI™ SureScan® Passive Fixation Leads Gives Physicians More MR-Conditional Options

MINNEAPOLIS--(BUSINESS WIRE)--Mar. 5, 2012-- Medtronic, Inc. (NYSE: MDT) today announced the receipt of CE Mark (Conformité Européenne) and launch of the CapSure Sense MRI™ SureScan® pacing...

Show per page